Table 1 Baseline demographic, clinical, and laboratory data for enrolled patients with CHA and HCV infection (n=21)
Characteristics | Frequency (%)/mean±SD |
|---|---|
Gender | |
Male | 10 (47.6%) |
Female | 11 (52.4%) |
Age (years) | 18–62 (median 33) |
BMI (kg/m2) | 24.4±3.67 |
Treatment status | |
Naïve | 20 (95.2%) |
Experienced | 1 (4.8%) |
Treatment duration | |
12 weeks | 8 (38.1%) |
24 weeks | 13 (61.9%) |
Diagnosis | |
β-Thalassemia major | 12 (57.1%) |
β-Thalassemia intermedia | 6 (28.6%) |
β-Thalassemia minor | 1 (4.8%) |
Sickle cell anemia | 1 (4.8%) |
Hemolytic anemia due to cryoglobulins and cold agglutinins | 1 (4.8%) |
Child-Pugh score | |
A | 13 (61.9%) |
B | 8 (38.1%) |
Blood transfusion | |
Regular | 18 (85.7%) |
Sporadic | 2 (9.5%) |
No | 1 (4.8%) |
Iron chelators | |
No | 9 (42.86%) |
Deferoxamine | 4 (19.05%) |
Deferiprone | 3 (14.28%) |
Deferasirox | 5 (23.81%) |